NDA 021153 describes NEXIUM, which is a drug marketed by Astrazeneca and Astrazeneca Lp and is included in one NDA. It is available from eleven suppliers. There are twenty-one patents protecting this drug and three Paragraph IV challenges. Additional details are available on the NEXIUM profile page.
The generic ingredient in NEXIUM is esomeprazole magnesium. There are fourty-nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the esomeprazole magnesium profile page.
|Active Rx/OTC/Discontinued:||RX||Dosage:||Capsule, Delayed Rel Pellets; Oral||Strength||EQ 20MG BASE|
|Approval Date:||FEB 20, 2001||TE:||RLD:||Yes|
|Patent:||4,508,905||Patent Expiration:||FEB 20,2001||Product Flag?||Substance Flag?||Delist Request?|
|Patent:||6,147,103||Patent Expiration:||OCT 09,2018||Product Flag?||Substance Flag?||Delist Request?|
|Patent:||6,166,213||Patent Expiration:||OCT 09,2018||Product Flag?||Substance Flag?||Delist Request?|
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.